E-DRUG: Survey reveals new data on financial transparency of patient and consumer organisations
---------------------------------------
Dear Readers,
Health Action International (HAI) Europe is publishing a research
article based on a survey on levels of financial disclosure and
transparency among patient and consumer organisations at the European
Medicines Agency (EMA).
Please see below some of the key findings from the study:
HAI Europe survey reveals new data on financial transparency of patient
and consumer organisations
* Two-thirds of the patient and consumer organisations working
with the European Medicines Agency (EMA) received partial or significant
funding from pharmaceutical manufacturers and/or industry associations.
This baseline data suggests that the pharmaceutical industry is the most
prevalent sponsor of the patient voice at the EMA.
* Fewer than half of the 23 organisations complied with EMA
financial reporting guidelines, which indicates the failure of the EMA
to effectively monitor and enforce its own guidelines on financial
transparency.
Please click here to read the Research Article
<http://www.haieurope.org/11082010/11_Aug_2010_HAI_Europe_Article-Patien
t_&_consumer_orgs_at_EMA_Financial_disclosure.pdf>
and Factsheet
<http://www.haieurope.org/11082010/11_Aug_2010_HAI_Europe_Factsheet-Pati
ent_consumer_orgs_at_EMA_Financial_disclosure.pdf>, or to be directed
to our website <http://www.haieurope.org/>
or blog
<http://www.haieuropestaffblog.blogspot.com/> .
For more information about this study, or its findings, please contact
Project Officer, Katrina Perehudoff at: Katrina@haiweb.org
Kind regards,
Katrina Perehudoff
Health Action International, Europe
Overtoom 60/II
1054 HK Amsterdam
The Netherlands
Tel: +31 20 683 3684
Fax: +31 20 685 5002
Email: katrina@haiweb.org
HAI Europe staff blog about recent developments in medicines policy at:
www.haieuropestaffblog.blogspot.com/
<http://haieuropestaffblog.blogspot.com/>
Health Action International (HAI) is an independent, global network
working to increase access to essential medicines and improve their
rational use through research excellence and evidence-based advocacy.